NYSE: GKOS

Glaukos (GKOS) Stock Analysis & Forecast

Nov 13 close

$245.72−0.31 (−0.1%)

Gekko Brief

AI summaryNov 9 close

Glaukos moves this week on record Q3 2026 results, with net sales of $211 million, up 58% year-over-year, a return to profitability, and raised full-year sales guidance, which together drove its inclusion in the S&P 400 and subsequent ETF inflows that altered the shareholder base. The company also shared a November 2026 investor presentation citing 30% 2025 growth projections, and announced an exclusive license agreement with RevOpsis Therapeutics to develop and commercialize RO-104, a tri-specific biologic for retinal diseases including wet age-related macular degeneration. A director's sale of 2,500 shares worth $632,500 was also disclosed via Form 4 filing.

The stock closes at $238.74, up 6.4%, sitting well above both its 50-day average of $179.44 and 200-day average of $144.82, with the 50-day above the 200-day. The GekkoIndex reads 46.3, placing it in the Neutral zone. Price stands 17.1% above Gekko Fair Value of $203.94.

Over the next 20 trading days, the next earnings date falls on 16 February 2027, outside this window. Thirty-day options activity shows 2 unusual signals, with put premium of $4,360,135 against zero call premium. Seasonality over 5 years shows an average 0% return across the next 20 trading days, with gains in 1 of those years. Consensus among 11 analysts stands at 10 buy, 1 hold, with a consensus target of $242.46.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Glaukos price vs fair value

$245.72$207.76Nov ’25May ’26Nov ’26
Close $245.72200-day averageGekko Fair Value $207.76

Glaukos quick facts

Market cap
$14.55B
P/E ratio
—
Forward P/E
1,666.7
EPS, TTM
−$2.95
Revenue, TTM
$690.3M
Profit margin
-24.6%
Dividend yield
—
Beta
0.68
Volume
542,918 avg 1.88M
1-year return
+165.3%
Typical daily move
±6.7%
Typical 20-day move
±8.2%
50-day average
$184.62
200-day average
$147.26
Next earnings
Feb 16 after close
Shares outstanding
59.20M
52-week range
$87.32$255.19

Glaukos swing-trade checklist

Glaukos scores 2 supportive, 1 mixed and 3 headwinds across the 6 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

2 supportive1 mixed3 headwinds

  • Trendsupportive

    Above 50 and 200-day

    Close $245.72 is above the 50-day ($184.62) and 200-day ($147.26) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    50.3, Neutral

    Reading 50.3 is in the Neutral zone.

    See the GekkoIndex
  • Fair valueheadwind

    18.3% above

    Price is 18.3% above Gekko Fair Value (more than 5% above).

    See fair value
  • Smart moneyheadwind

    Leans bearish

    Last 30 days: 2 unusual options signals.

    See smart money
  • Earnings risksupportive

    Reports in 93 days

    Next report Feb 16, 2027, 93 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalityheadwind

    −1.6% on average

    From this point in the calendar, the next 20 trading days averaged −1.6% over 5 years, rising in 1 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Glaukos stock chart and price history

Glaukos closed at $245.72 on Nov 13, 2026, +165.3% over the past year, inside a 52-week range of $87.32 to $255.19.

Close50-day average200-day averageVolume
Glaukos share price, past year, with 50-day and 200-day moving averages and volume$100$150$200DecJan 2026FebMarAprMayJunJulAugSepOctNov245.72

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+48.4%
3 months
+32.4%
6 months
+70.6%
1 year
+165.3%
The full GKOS chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open GKOS in Gekko

Follow Glaukos through every session

Put GKOS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track GKOS in GekkoFree for 7 days. No credit card required.

About Glaukos

Glaukos develops medical devices and pharmaceutical products for eye conditions, with particular attention to glaucoma along with corneal and retinal disorders. It is best recognized for its micro-bypass stent line, including iStent, iStent inject, and iStent inject W, small devices implanted during cataract surgery to help fluid drain from the eye and ease mild-to-moderate open-angle glaucoma. Beyond these established products, the company is advancing iStent Infinite, a three-stent option meant to be used on its own for harder-to-treat glaucoma cases, and iDose TR, an implant built on its micro-scale technology that delivers medication directly to the eye over time.

Glaukos reaches physicians and patients through its own sales force as well as outside distributors, with sales spanning both domestic and international markets.

The company was founded in 1998 and is based in San Clemente, California. Its shares trade on the NYSE under the ticker GKOS.

Listed
NYSE
Sector
Health technology
Industry
Medical specialties
Website
glaukos.com

Glaukos GekkoIndex: the smart money zone

Glaukos’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 50.3, in the Neutral zone, up 5.1 points over five sessions.

010050.3Neutral

Up 5.1 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying34+0.9%+2.1%+5.0%+10.1%
Accumulation164+1.0%+1.7%+4.8%+12.9%
Neutral (current zone)448+0.9%+1.7%+2.5%+5.5%
Distribution48+0.8%+1.0%−0.5%+4.2%
Selling8Too few readings yet

Average GKOS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the GKOS price, zone by zone.Track GKOS in Gekko

Is Glaukos stock overvalued? Gekko Fair Value

Glaukos trades 18.3% above Gekko Fair Value of $207.76, so the shares are overvalued on Gekko’s estimate.

Gekko’s own estimate of what Glaukos shares are worth, recalculated every trading day.

$207.76

Gekko Fair Value, Nov 14, 2026

18.3% Overvalued

At the end of Aug 2026 the price was 3.1% below the estimate.

Gekko Fair ValueShare price, month end
$208$246Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open GKOS in Gekko

Glaukos insider and Congress trading

No open-market insider purchases were filed for Glaukos, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for GKOS in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every GKOS insider filing, plotted on the chart in Gekko.Open GKOS in Gekko

Congress trades last 90 days

No trades in GKOS were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for GKOS, plotted on the chart in Gekko.Open GKOS in Gekko

Buybacks

Glaukos has been buying back its own shares.

Bought back, quarter ended Jun 30, 2026
$2.79M
As a share of market cap
0.02%

From company filings.

Unusual options activity last 30 days

2signals, 0% of the flagged premium in calls.

Latest: Bearish flow on Nov 6, $3.87M in unusual premium.

Hedge funds and billionaires quarter ended Jun 30

1of the funds Gekko tracks holds GKOS.

0added1opened0trimmed0sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko

Glaukos earnings: next date and track record

Glaukos reports on Feb 16, 2027, after the close (93 days away), and beat the EPS estimate in 6 of its last 8 reports.

6 of 8reports beat the EPS estimate
±16.2%average move across the report
5 of 8reports followed by a gain

Share-price move across each report

−21.6%Feb ’25−11.0%Apr ’25−8.2%Jul ’25+12.9%Oct ’25+10.5%Feb ’26+20.1%Apr ’26+11.4%Jul ’26+33.8%Oct ’26

Last earnings call, Oct 28, 2026 AI summary

What they said
Glaukos reported record Q3 2026 net sales of $211 million, up 58% year-over-year. Non-GAAP gross margin expanded ~400 basis points to ~88%, with $28.5 million non-GAAP net income and EPS of $0.47. Cash generation exceeded $50 million. Growth is driven by iDose TR in interventional glaucoma and Epioxa launch for keratoconus.
Guidance
Full year 2026 net sales guidance raised to $775M-$785M, up $90M at midpoint from prior $680M-$700M range. Preliminary 2027 revenue guidance introduced at $1 billion, reflecting Epioxa and iDose TR commercial rollout.
ReportedEPSSurpriseRevenueSurpriseMove
Oct 28, 2026$0.47
est −$0.10
+587.8%$211.0M
est $168.0M
+25.6%+33.8%
Jul 29, 2026−$0.14
est −$0.28
+50.0%$185.6M
est $150.9M
+23.0%+11.4%
Apr 29, 2026−$0.18
est −$0.28
+35.7%$150.6M
est $137.0M
+9.9%+20.1%
Feb 17, 2026−$0.28
est −$0.22
−27.3%$143.1M
est $136.4M
+4.9%+10.5%
Oct 29, 2025−$0.16
est −$0.27
+40.7%$133.5M
est $129.5M
+3.2%+12.9%
Jul 30, 2025−$0.24
est −$0.26
+7.7%$124.1M
est $122.4M
+1.4%−8.2%
Apr 30, 2025−$0.22
est −$0.35
+37.1%$106.7M
est $102.8M
+3.8%−11.0%
Feb 20, 2025−$0.40
est −$0.39
−3.0%$105.5M
est $101.0M
+4.5%−21.6%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Glaukos stock forecast and analyst price targets

Analysts’ average 12-month price target for Glaukos is $242.46, −1.3% from the last close, from 11 firms rating the stock in the last 90 days.

$242.46consensus 12-month target, −1.3% from the last close
Low $210High $255
Buy10
Hold1
Sell0

Each firm’s latest rating in the last 90 days: 11 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 2UBSHold, maintained$241−1.9%
Oct 30H.C. WainwrightBuy, reiterated$248+0.9%
Oct 29CitiBuy, maintained$247+0.5%
Oct 29Stifel NicolausBuy, maintained$225−8.4%
Oct 29NeedhamBuy, reiterated$251+2.1%
+2.5%average 20-day move after past Neutral readings
−1.6%average move over the next 20 trading days in the last 5 years
±6.7%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Glaukos seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Glaukos averaged −1.6% across the last 5 years, rising in 1 of them.

Next 20 trading days, by year

−11.7%2021−9.7%2022−8.5%2023+0.2%2024+24.1%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−1.1%1 of 5
Next 10 trading days−2.1%1 of 5
Next 15 trading days−2.9%1 of 5
Next 20 trading days−1.6%1 of 5
Next 30 trading days+6.0%3 of 5

For scale, GKOS’s typical 20-trading-day move in either direction is about 8.2%.

Glaukos market cap and key statistics

Glaukos’s market cap is $14.55B and revenue of $690.3M over the last twelve months.

Valuation

Market cap
$14.55B
Forward P/E
1,666.7
EPS, TTM
−$2.95
Gekko Fair Value
$207.76

Trading

Volume
542,918
Avg volume, 20 days
1.88M
52-week high
$255.19
52-week low
$87.32
Shares outstanding
59.20M

Financials

Revenue, TTM
$690.3M
Profit margin
-24.6%
Return on equity
-22.8%
Quarterly earnings growth, YoY
+1,896.0%

Risk and income

Beta
0.68
Typical daily move
±6.7%
Typical 20-day move
±8.2%

Glaukos stock news this week

Coverage of Glaukos this week reads neutral: 4 positive, 5 neutral and 2 negative headlines.

News sentiment neutral

Glaukos peers

Glaukos’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
TMOThermo Fisher Scientific−0.2%Neutral15.0% above
ABTAbbott Laboratories+0.3%Neutral10.5% below
DHRDanaher0.0%Neutral4.7% above
ISRGIntuitive Surgical0.0%Neutral17.5% above
MDTMedtronic+0.7%Neutral14.2% below
SYKStryker−2.0%Neutral0.1% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Medical specialties

Glaukos stock FAQ

What is Glaukos’s market cap?

Glaukos’s market cap is $14.55B at the Nov 13, 2026 close of $245.72, with 59.20M shares outstanding.

What is the Glaukos stock forecast?

The consensus analyst 12-month price target for Glaukos is $242.46, −1.3% from the last close. Of the 11 firms that rated the stock in the last 90 days, 10 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Glaukos stock overvalued or undervalued?

On Gekko’s estimate Glaukos is overvalued: the Nov 13, 2026 close of $245.72 is 18.3% above Gekko Fair Value of $207.76. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Glaukos report earnings next?

Glaukos is expected to report on Feb 16, 2027, after the market closes (93 days away). Analysts expect earnings of $0.50 per share on revenue of $233.3M. Glaukos beat the earnings estimate in 6 of its last 8 reports, moving 16.2% on average across the report.

What is Glaukos’s 52-week high and low?

Glaukos’s 52-week high is $255.19 and its 52-week low is $87.32; it closed at $245.72 on Nov 13, 2026, +165.3% over the past year.

Is Glaukos stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 6 items with data read as supportive (trend and earnings risk), 1 as mixed (gekkoindex) and 3 as headwinds (fair value, smart money and seasonality). The checklist is a description of current data, not a recommendation.

Is there unusual options activity in Glaukos?

Gekko flagged 2 unusual options signals in Glaukos over the last 30 days, with $0 of flagged premium in calls and $4.36M in puts. The latest, bearish flow, was on Nov 6, 2026 with $3.87M in unusual premium. The signal-by-signal table is in Gekko.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Glaukos the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.